Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AIMD Ainos	$3.81 -4.3%	$3.01	$2.00 ▼ $5.00	$17.76M	2.2	953,499 shs	58,875 shs
ATNF 180 Life Sciences	$2.87 -3.7%	$2.98	$0.66 ▼ $17.75	$17.33M	0.38	22.03 million shs	7.91 million shs
LEXX Lexaria Bioscience	$0.88 -0.9%	$0.88	$0.77 ▼ $4.38	$17.23M	0.79	144,951 shs	38,420 shs
ONCO Onconetix	$2.95 -1.8%	$3.69	$2.61 ▼ $552.50	$4.59M	3.37	371,867 shs	18,336 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AIMD Ainos	+4.74%	+15.03%	+63.11%	+17.96%	+26.09%
ATNF 180 Life Sciences	-3.87%	-43.02%	-7.45%	+192.16%	+53.61%
LEXX Lexaria Bioscience	+0.49%	+13.25%	+0.10%	-11.88%	-69.52%
ONCO Onconetix	+2.04%	+6.76%	-17.13%	-52.24%	-99.37%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AIMD Ainos	1.0606 of 5 stars	0.0	3.0	4.3	1.7	0.0
ATNF 180 Life Sciences	1.0009 of 5 stars	0.0	2.0	3.8	1.7	0.6
LEXX Lexaria Bioscience	3.7851 of 5 stars	3.5	5.0	3.1	3.3	0.6
ONCO Onconetix	1.1059 of 5 stars	0.0	4.0	3.8	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AIMD Ainos	0.00	N/A	N/A	N/A
ATNF 180 Life Sciences	0.00	N/A	N/A	N/A
LEXX Lexaria Bioscience	3.00	Buy	$4.00	353.51% Upside
ONCO Onconetix	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ONCO, AIMD, ATNF, and LEXX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
7/29/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
7/29/2025	LEXX Lexaria Bioscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $4.00
7/12/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
7/1/2025	LEXX Lexaria Bioscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$7.00 ➝ $5.00
6/27/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
6/11/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AIMD Ainos	$20K	887.73	N/A	N/A	$2.46 per share	1.55
ATNF 180 Life Sciences	N/A	N/A	N/A	N/A	$2.91 per share	N/A
LEXX Lexaria Bioscience	$615.92K	28.01	N/A	N/A	$0.48 per share	1.84
ONCO Onconetix	$2.52M	1.81	N/A	N/A	$3.82 per share	0.77

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AIMD Ainos	-$14.86M	-$4.99	N/A	∞	N/A	N/A	-108.25%	-56.94%	11/4/2025 (Estimated)
ATNF 180 Life Sciences	-$6.17M	-$15.07	N/A	∞	N/A	N/A	-141.25%	-80.77%	11/12/2025 (Estimated)
LEXX Lexaria Bioscience	-$5.80M	-$0.67	N/A	N/A	N/A	-1,849.19%	-157.22%	-133.69%	N/A
ONCO Onconetix	-$58.69M	N/A	0.00	∞	N/A	-3,327.03%	-192.74%	-89.55%	N/A

Latest ONCO, AIMD, ATNF, and LEXX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ONCO Onconetix	N/A	-$4.05	N/A	-$4.76	N/A	$0.11 million
8/13/2025	Q2 2025	AIMD Ainos	N/A	-$0.99	N/A	-$0.99	N/A	N/A
7/23/2025	Q2 2025	ATNF 180 Life Sciences	N/A	-$0.30	N/A	-$0.30	N/A	N/A
7/14/2025	Q3 2025	LEXX Lexaria Bioscience	-$0.15	-$0.21	-$0.06	-$0.21	$0.17 million	$0.17 million
6/12/2025	Q1 2025	ONCO Onconetix	N/A	$21.25	N/A	-$0.53	N/A	$0.10 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AIMD Ainos	N/A	N/A	N/A	N/A	N/A
ATNF 180 Life Sciences	N/A	N/A	N/A	N/A	N/A
LEXX Lexaria Bioscience	N/A	N/A	N/A	N/A	N/A
ONCO Onconetix	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AIMD Ainos	0.96	2.88	2.61
ATNF 180 Life Sciences	N/A	0.58	0.58
LEXX Lexaria Bioscience	N/A	3.90	3.90
ONCO Onconetix	N/A	0.07	0.06

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AIMD Ainos	N/A
ATNF 180 Life Sciences	4.07%
LEXX Lexaria Bioscience	13.06%
ONCO Onconetix	23.89%

Insider Ownership

Company	Insider Ownership
AIMD Ainos	10.39%
ATNF 180 Life Sciences	38.20%
LEXX Lexaria Bioscience	26.40%
ONCO Onconetix	3.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AIMD Ainos	40	4.66 million	4.17 million	Not Optionable
ATNF 180 Life Sciences	7	6.04 million	3.73 million	No Data
LEXX Lexaria Bioscience	7	19.56 million	14.40 million	Not Optionable
ONCO Onconetix	12	1.55 million	1.50 million	N/A

ONCO, AIMD, ATNF, and LEXX Headlines

Recent News About These Companies

Onconetix Director Resignation Amid Financial Adjustments

August 12, 2025 | msn.com

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Onconetix, Inc. (NASDAQ: ONCO)

July 17, 2025 | globenewswire.com

Onconetix, Inc.: Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreement

July 16, 2025 | finanznachrichten.de

Onconetix Shares Touch All-Time Low on Reverse Merger With Ocuvex

July 16, 2025 | marketwatch.com

ONCO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Onconetix, Inc. Is Fair to Shareholders

July 16, 2025 | businesswire.com

Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreement

July 16, 2025 | globenewswire.com

Onconetix, Inc. Announces Positive Decision by Nasdaq Hearings Panel

June 16, 2025 | globenewswire.com

Onconetix, Inc. Announces Approval of 1-for-85 Reverse Stock Split by Stockholders

June 13, 2025 | nasdaq.com

Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders

June 11, 2025 | globenewswire.com

Onconetix faces potential Nasdaq delisting over filing delays

May 24, 2025 | investing.com

Onconetix receives additional delisting notice from Nasdaq

May 23, 2025 | finance.yahoo.com

Onco-Innovations Announces Appointment of Professor Steven Jones as Senior Scientific Advisor, Strengthening Technical Acumen in AI-Powered Precision Oncology

May 22, 2025 | accessnewswire.comA

Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq

May 22, 2025 | globenewswire.com

Onco-Innovations Uplists to Cboe Canada

May 22, 2025 | businesswire.com

Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq

April 30, 2025 | globenewswire.com

Onconetix faces third delisting threat since 2022 IPO

April 21, 2025 | bizjournals.com

Onco-Innovations Announces Partnership with Dalton Pharma for Isotope Synthesis of Patented PNKP Technology

April 17, 2025 | accessnewswire.comA

Onco-Innovations Announces Private Placement

April 16, 2025 | accessnewswire.comA

Onconetix Inks Letter Of Intent For Potential Business Combination With Ocuvex

April 10, 2025 | nasdaq.com

Five things you need to know today, and calming irrational fears

April 9, 2025 | bizjournals.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCO, AIMD, ATNF, and LEXX Company Descriptions

Ainos NASDAQ:AIMD

$3.81 -0.17 (-4.27%)

As of 03:23 PM Eastern

Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.

180 Life Sciences NASDAQ:ATNF

$2.87 -0.11 (-3.69%)

As of 08/28/2025

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.

Lexaria Bioscience NASDAQ:LEXX

$0.88 -0.01 (-0.90%)

As of 03:51 PM Eastern

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

Onconetix NASDAQ:ONCO

$2.94 -0.06 (-1.83%)

As of 03:52 PM Eastern

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time